NCOA3 and lymphoma: To evaluate the in vitro anti-lymphoma activity of SI-10 and SI-12, four MCL lines and one murine lymphoma line were treated with either SRC-3 inhibitor SI-10 or SI-12 at concentrations ranging from 0–2 μM.